International Journal of Current Advanced Research
ISSN: O: 2319-6475, ISSN: P: 2319-6505, Impact Factor: 6.614
Available Online at www.journalijcar.org
Volume 8; Issue 04 (C); April 2019; Page No.18228-18234
DOI: http://dx.doi.org/10.24327/ijcar.2019.18234.3479

Research Article

CLINICAL OUTCOME IN ATRIA FIBRILLATION AT GENDER DIFFERENCES: META- ANALYSIS

***Hassah Iftikhar, Hassam Ali and Ya Li**

Department of Cardiology, Renmin hospital of Wuhan University, 430060, Wuhan, Hubei Province, PR China

A R T I C L E I N F O

Article History:
Received 10th January, 2019
Received in revised form 2nd February, 2019
Accepted 26th February, 2019
Published online 28th April, 2019

Key words:

Atrial fibrillation, CVD risk factors, anti-thrombic therapy.

A B S T R A C T

Background: Atrial fibrillation is the all-cause risk factors of CVD in females compared to males in the risk ratio of IHD and DM.
Purpose: To characterize the safety efficacies of anti-thrombic agent's use in the controlling adjustments of treatment preventing ischemic stroke, adding 10 randomized trials to a previous meta-analysis.
Data sources: Identified relevant trials in the literature of bibliography reviews, MEDLINE, and Cochrane (CENTRAL strategy from 2011-2016) obtaining the unpublished data existing in the finding of antithrombic therapy.
Study selection: As the published clinical trials tested controlled endpoints of recovery included in the participation of 987 participants with 6-month long-term atria fibrillation dependent on titrated dosing agents.
Data extraction: Selected studies in the inclusion describe the ascertainment of diagnostic monitoring experience the outcome of SCD in the relevance of cardiac events, HF, MI and all-cause mortality differentiating the interventional hypothetic prevention.
Data synthesis: In 27 study trials included 23,040 participants mean follow-up of (6month-1 year). Compared with warfarin dosing (5 trials, 2400 participants) and antiplatelet agent (7 trials, 4776 participants) in the reduction of 69% and 32% respectively. And without adjustment substantially carry relative risk reduction 44% and 13% (11 trials, 11920 participants).
Limitations: The eligibility of method feature and insufficient data on the impact of post-MI is reported incomplete.
Conclusion: The adjusted-dosing in warfarin and antiplatelet agents are 40% and 34% respectively in the risk factors of AF. Substantially, warfarin remains more efficient by approximately 24% then anti-platelet. The absolute increase of major hemorrhage in the association of trial participants judicious the importance of antithrombic medication in the importance of cardiac-neuro risk factors.

INTRODUCTION

The dependency of approximate 6 million people at 5 fold risk factors of stroke (1, 2) doubles the expectancy of valvular heart disease in the reoccurrences of embolic events based on several meta-analyses. The Framingham heart study (3, 4) demonstrates the impact of recognized MI sustainability in the adjustments of chronic symptoms to the pivotal study prognostic of high hemodynamic effect.

As based on diversity of the mean population, clinical trials carry a wider range of practical characteristic in the likelihood of collaborative effort identifying CVD advancements at the early stage of existing CVD history continuum to the probability of scoring rate in females.(5) Moreover, the calculated 10 years in the intermediate category implement the consideration of health care longevity of life expectancy. (6) The tested participants of total 10,000 randomized trials update the maximal efficacies and safety therapies from the extracted previous published research including the number of treatment duration on antithrombic dosing confounding the average of subset of the AF selective to long-term weeks study. (7, 8) The importance of significant AF in the percentile of female measures recommends the guidelines based on higher death consequences in the prevalence of arrhythmias.

In addition, certain prevalence at the rate of mortality interval twice increases the proportional risk growth between both the genders in an association of CHD. (9, 10) Hence, the general population of multi-variate in the implication of difference at regional burdens on management accordingly differential diagnosis the unclear relative diseases factor. The ethnic of preventive proportionality include fatal and non-fatal causes initiate the studies of (HER) at women's health in heart and estrogen (progestin replacement therapy) in the practices of

Corresponding author:* **Jiang Hong
Department of Cardiology, Renmin hospital of Wuhan University, 430060, Wuhan, Hubei Province, PR China

adverse events qualitatively and quantitatively based on evidence of support recording the recent observed chronic factors in a generalized setting.

Lastly, elderly groups associated to routinely monitored diseases count the leading decrease of carbon dioxide (11) emphasizing ischemic cerebrovascular causes cohort to suggested impaired blood flow in the estimation of sizes interaction diminishing the ischemic perfusion. (12) Indeed, warfarin illustrates numerous stages exerting the concerns of protective effect at atherosclerosis that also matter in comparison of antithrombic medication.

METHODS

The identified randomized trials randomize the use of antithrombic agents in search at PUBMED and EMBASE in the systematic reviews of ACS referring SCD in symptoms of angina prospective of follow-up analysis.

The cohort limitation of OR trial with RR studies potentially extract the criteria of post-operative exclusion outcome in the importance of primary enrolled outcome widely based on HF. The consensus of disagreement in the identified reports of 4 trials excludes 8 randomized trials prolonging the normalized ratio of aspirin and warfarin use of alone to annualize the result of controlled group effect assumption at P value 0.005.

Data extraction

The eligible approach of study characteristic in the means of follow-up at the outcome of history based analysis (mean age, stroke, CHD and HF) specifically counter the sex rate death ratio maximal of 95% confidence interval cohort to larger events. The study quality assesses the meeting of inclusion study abstracting work on years designing study of participants at diagnostic method prior to MI calculation curding CVD treatment plan with standard goals of monitoring HTN, BMI, and pre-surgery conditions. The unconventional method in aspects incorporating compatibility at ranging social – economical medium at higher quality. And the sources of methodologies wide range the paradigm consistency of hemorrhage in remaining of fractional to neuro-imaging of ischemic stroke.

Data synthesis

The key featuring of material follow the preventive strategies at www.annals.org the absolute risk and risk reduction at controlled lard and persimonian method (13) annualize the total eventual rates. (46) The overall notable treatment preclude the estimation of P-value subtracting the significance of considerate results by doubled sided values at (Medcalc Mariakerke and SPSS, Chicago, Illinois)

RESULT

The systematic research of identified screening 3675, the examined 3370 in full-text review and 242 were excluded. Accordingly, we include 34 quantitative studies. Figure 1 None of this studies reported life-threatening risk factors associating sex determination. The 21 studies provided published work and co studies of unpublished data; Table 1 shows the included studies ascertainment of AF within of ECG recording 17 studies, 9 studies of medical records and 5 combined studies. Two study reports SCD in the method of ascertainment assessing New castle-Ottawa scale. The overlapping 57 studies, 1000 participants respectively include the relative risk of CVD events, DM, HF, and all-cause mortality.

Table: 1 Characteristic of included cohort studies that reported AF in men's and women's. The exposure of 6 months participants impact of risk factors n=30, average the treatment at post surgeries with medication carrying n=30 and n=11 significantly. Mostly the trials varying measurements of antithrombic and anticoagulants with and without combined drugs intensity of LMWH, ACEIs/diuretics vs digoxin/βblockers and anti-platelet = aspirin + clopidogrel.

Table 1 Characteristic of included cohort studies that reported AF in men's and women's

Study year	Study design	AF ascertainment	Tot no. of AF n value	Age group	Female %	Number of individuals at baseline				Maximum adjustment	CV outcome
						IHD	Stroke	previous MI	DM		
Aguilar 2012	Prospective	Medical records	3,848	58	25.8%	87%	65%	37.3%	41%	NONE	MI, DM,CHD
Martinez 2014	Retrospective	Medical records	30,260	71	39%	40%	27%	4.7%	23%	NONE	MI
Solimen 2014	Prospective	Records +ECG	23,928	54	59.1%	16.6%	14.8%	0	13%	+++	MI
Anderson 2014	Prospective	Medical records	21,987	59	68%	NA	NA	32%	78%	Adjusted by ages	IHD,DM
Vermond 2015	Prospective	ECG	8,265	49	50.2%	60%	10%	3%	40%	Adjusted	CV cardiac events
Li 2015	Retrospective	Medical records	704,225	>18	44.4%	19%	39%	NA	43%	+++	CV events
Parisi 2015	Prospective	Medical records	256,710	48	56.4%	14%	10%	NA	19%	+++	CV events
Hippisley-Cox 2015	Prospective	Medical records	437806 (13953)	60	68%	NA	NA	23%	18%	HDL, DMT1, CVD, CKD	dyslipidemia
O'Neal 2016	Prospective	Records +ECG	4304	>65	61%	40%	15%	63%	NA	+++	CHD, MI
Shih 2016	Retrospective	Medical records	12,988	69	53.3%	24%	45%	14%	50%	+++	CV death, MI

Table 2 Baseline characteristics of females and males hospitalized with chronic AF

CO -morbidity profiles	Females n=163	Males n=175
CVD profile		
CAD	42(25.8%)	76(41.3%)
Diabetes	43(28.1%)	52(30.1%)
Stroke/TIA	26(14.0%)	33(18.9%)
Depression/stress	62(39.8%)	43(22.3%)
Mean LVEF%	62.3±10.6)	55.4±12.0%
Mean total cholesterol (nmol/L)	4.6±1.4	4.4±1.3
Obesity (BMI≥30kg/m2)	69(47.7%)	45(32.3%)
Hormonal replacement therapy	68%	32%
Cardiac –neuro rehabilitation	45%	77%
Pre/post surgery	2:1	1:1
Antecedent		
Mean HR before treatment	108±37	99±34
Mean HR after treatment	76±17	78±19
Paroxysmal AF diagnosis%	6(3.1%)	10(5.6%)
Permanent AF diagnosis %	18(12.6%)	19(9.9%)
Treatment profile		
BP management	102(62.3%)	116(65.4%)
Anti platelet	52(32.1%)	50(29.8%)
B-blocker therapy	77(48.7%)	83(50.2%)
Warfarin in AF	89(54.0%)	98(57.9%)
Aspirin in primary prevention	76(47.6%)	87(49.3%)
Heparin	41(32.0%)	48(42.1%)
ACE/ARBs therapy	35(29%)	42(30%)
Diuretics	85(53.2%)	56(32.6%)
Digoxin	65(40.2%)	59(30.5%)
Aspirin +Clopidogrel %	36(29.8%)	47(27.9%)



Figure 1 Identification of cohort studies-reporting association between AF and SCD related to CVD in gender differences.



Figure 2 maximally adjusted relative risk for all cause mortality for individuals with AF in sex differences inversely remained variant proportional in the estimation of 95% confidence interval.

Table 3 All-cause mortality analyses

Variables	Adjusted Warfarin dose Control	Adjusted Aspirin dose Control	Adjusted Total Treatment
Patients, n	323	478	431
Intracranial hemorrhage			
Events, n	3 vs 2	7 vs 6	21 vs 8
Absolute risk reduction %	NL	NL	-0.2
Extracranial hemorrhage			
Events, n	20 vs 14	15 vs 13	30 vs 22
Absolute risk reduction %	-0.4	-0.3	0.2
Ischemic stroke			
Events, n	46 vs 32	21 vs 17	-70 vs 117
Absolute risk reduction %	-0.6	-0.3	0.2
All-cause mortality			

Table 4 Safety outcomes for major antithrombic comparison

Death, n	32 vs 43	56 vs 72	92 vs 118
Relative risk reduction %	27 (4 to 52)	12 (-7 to 21)	10 (-18 to 36)
Absolute risk reduction %	1.9	0.8	0.5

Table 5 Meta-analysis of the efficacy of antithrombic treatment in the therapies of ischemia prevention in AF patients

Comparison	Relative risk reduction %	Hypothetical primary prevention	Hypothetical secondary prevention
Adjusted-control warfarin dosing	69%	45%	46%
Without adjustment Warfarin therapy	44%	30%	24%
Adjusted-control Anti-platelet agents	32%	79%	34%
Without adjusted Anti-platelet	13%	51%	21%

Calculated relative risk reduction analyzed the hypothetical rates to yield primary prevention of control group of n=5% receiving antiplatelet per year 17% and prior to ischemic stroke n=10% receiving secondary prevention.

In the assignment of the number of participants involved both controlled groups of males and females result in n value of females 163 and n=175 in males in the measures of rehabilitation between 45% -77%restricting primary prevention trial in the previous conditions of ischemic stroke on secondary prevention at 1.5% per year. The selective onset symptoms intervention, aspirin therapy closely recommend dosing between 160-300mg grading 1A respectively. Moreover, pneumatic condition with restricted mobility and TIA prophylaxis, heparin treatment on grading 2B respectively. And at long-term recommended aspirin + clopidogrel (75-100mg/daily with an alternative of antiplatelet therapy require oral anticoagulant medication. Therefore, the recommendation of antiplatelet regimen suggestive of clopidogrel over aspirin, we prefer anti-coagulants with adjustment of absolute risk reduction in both the genders percentage equal to 0.2 relative risk reduction of 0.5.

CONCLUSION

Evidence-based medication strategy leads to the stroke risk factor in particular at hypothetical combined prevention.

Anti-platelet

The framework of anti-platelet responses compromised the hypoxia disrupting the blood circulation physiologically in the phases at propagating amplified functioning of coagulation factors mediating over the surface platelet receptors. The prevalence in the concern of higher reactivity using clopidogrel in females (14, 15) evaluates the relative risk based on (WHS) evaluation over 50 years randomizing aspirin approximate of 1.4 times collaborating (ATT) antithrombic trialists within the hypothesis of cardia-protection definitive to literacy conclusion. Moreover, in the occurrences of migraine, smoking and OCP related symptoms basically involved SLE and APL at American Stroke Association (ASA) collaborating Anti phospholipids antibodies and stroke (APA) versus warfarin –aspirin recurrent stroke strategy (WARS)comparing normalized warfarin calculating the ratio of 1.4-2.8 equal to aspirin 325mg composite to the endpoints of mortality rate provoking arterio-venous occlusion leading multi and vascular death at risk of 20% in both sexes (16) carry long-term ACS to optimize thrombolysis (TIMI) trials, undergo revascularization expecting reoccurrences in the events of 12-15 months particularly in females. (17)

The evidence based on outcome and high grade of relative effect in participants observed recurrent stroke, non-fatal

hemorrhage, extracranial hemorrhage that high-risk cancer risk factor within the addition of aspirin> 5 years. The average based 1000 participants analysis attribute 50% of death tribute at vascular causes in the balances of the history of diseases favoring clot within the noticeable change of 20% aspirin treatment. In the consideration of the radial artery closure effectiveness prior selection of antithrombic drugs that greatly aware of the intensity of management measuring actual weight in calculating adjustments of creatinine levels in females.

At another trial significance of platelet inhibitions and patient outcome (PLATO) dual the outcome of anti-platelet for consistent bleeding risk enrolling rapid stratified suppression in unstable angina implementing adverse event in the early phase at register based ACC/AHA (CRUSADE) guidelines respective to males at the site of bleeding P <0.0001 accessibility. The equivalent efficacies responsive in females with propensity at high dosing excessively contribute sex disparities in ACS diminish. The observed conservative management at non-invasive conditions in STEMI cases receives perfusion (19) on high demands of mortality (20) at risk profiles og angiography. (21, 22) The consecutive adherence involving lipid-lowering medication, ACE, and aspirin started the interaction after the discharge from the hospital more effectively higher in females as compared to males that only recommend discontinuation at the end when interrupting discharge bleeding at responses of close monitoring (23) in premature conditions. Therefore long-term meta-analysis strongly predicts ARG independence of types in relating complications as seen in Table: 2

Anti-Coagulation

The investigation on arrhythmia management (AFFIRM) describes the therapeutic range of prolonging time significance in a group of sex differences P=0.001. The estimated women's at the high rate of protection against (CHADS) CHF, HTN, age and diabetes, and prior stroke suggest parameter of thromboembolic risk factors that obtain aggressiveness in the treatment of anticoagulation therapy. (24) And at the annual rates of complications require RR of (1.8%, 95CI 1.3-1.9) relying on lower incidence of bleeding complication. (25)

The observational study support path physiological underlying mechanism that validates the biological factor in females explaining incidences of 82% in females is greater risk diminishing the simultaneous proportionate of MI in the prevalence of DM and HTN at middle age worsening the prognosis of CHD exposure. And at the haemostatic changes of hormonal replacement therapy globalize setting of venous thromboembolism (VTE) explaining the pro-inflammatory mediators in the presence of micro-vascular dysfunctions altering metabolic rate that directly effect on estrogen, progesterone and androgen levels on platelets greatly fluctuating RAAS metabolism determine early phases with reduced BMI, reintroducing inappropriate use of antithrombic medication for long-term continuation subsequent to anti-platelet. Furthermore, anti coagulants use must not accelerate results of aging and fatal stroke adhering disability in severity at P value 0.001(26) in the confirmation of stroke in males at multi-variant co morbidities on the basis of females gender appearing (CH2 DS2-VA/2)seen at Figure .2 and Table. 3

Figure: 2 maximally adjusted relative risk for all cause mortality for individuals with AF in sex differences inversely remained variant proportional in the estimation of 95% confidence interval.

Hence, study on AF according to gender control direct the use of anticoagulants orally resulting warfarin efficacies to remain stable in both genders at the ratio of hemorrhage. The adverse events showed no clear differences at the high rate of bleeding in males and slight high risk of stroke in females respectively.

The Combined effect of anticoagulants and anti-platelet

The past studies on platelet activation derived β-TG at the parameters of D-dimers, prothrombin, and fibrinogen to abundant the required primary and secondary preventions at the incidences of systematic embolism and stroke. The findings on dual effects inhibit the modulation of substantials in NVAF cases further with no clear evidence. The risk of embolism complications in the processes of mechanisms at hypercoagulability reactivity irregularly persistent the injuries in the adhesiveness of monolayer flow at endothelium.

The anti-coagulation effects in the measurements of PTT remained unaffected structurally in the inhibiting processes with the contrast of heparin, under circumstances of clotting activation. (28) The evidence of thromboprophylaxis at 65% of TE risk factors acquired 22% no useful results to tackle the high-risk vascular events up to 20%. Therefore the combined mono dual medication therapy in AF concomitant CHD in undergoes the stent strategies.

However, the property of thrombogenicity epitomized the grafting method at the recombinant trials on animals for the restenosis of plasminogen that is accelerating the delaying of heparin for the better situation of aspirin use. (27, 28, 29, 30) The tolerability of bleeding risk factors in the aspirin therapy created adhere events on IV nitroglycerin infusion at the probable minor conditions documenting antithrombic effectiveness in favors of clinical activity meeting the standards of excellence at safer profiles on the symptom of unstable angina. And also at the close monitoring of heparin treatment, plasma proteins responded neutralization episodes aggregating the ischemic episodes. At invivo, half-life fibrinopeptide, the systemic activity proved an efficient significance of thrombin factor variable to aPTT staging differentiating both the optimal drugs to coronary diseases. Therefore, the prolonged aPTT yields therapeutic heparin, in which access visibility is quite difficult. Clinically, the high rate of subjects in occlusion studies achieved 95% success in designing unequal population-based sites. Thus, comparative to anti-anginal medication observed an increase in plasma rates at reoccurred injuries rebound the associations of anti-coagulants at isolated use. (31)

DISCUSSION

The history based cardiovascular incidences on outcome average the results in ACS revascularization and HF events in males at follow-up of 1 year. The prediction of AF symptoms consistently reported increased symptoms, the high risk asymptomatic conditions in females. (32,33) Secondly, the sinus rhythm in the observational study at gender differences copies a method of earlier known warrants at symptoms in reoccurrences for the further perception. The pharmacological treatment in the maintenance of preserving ablation therapy it demands an anti-arrhythmia at the cardioversion prevalence versus surgical intervention. (33, 34) Moreover, the invasive technique at the females reacts decreasingly in valvular condition conserving hyperactive reactions. (35) Similarly,

HF also counters severe complications with susceptibility of equivalent 1-year duration examining reduced EF intending the development of preserved EF in females. Additionally, the occasion of AF symptoms varies with fatigue, palpitation, and dyspnea at a common feature of angina with the ratio of 35% in females and 27% in males frequently prescribe anticoagulation therapy at 2 fold baseline follow-up. The strengthened ability of clinical assumption, on time associated the validity of males target positivity diversifying the assessment of HAS-BLED and CHA2DS2 predictors.

The epidemiologically based counterpart weaker the risk assessment in the ratio of females: males that experience CAD generally due to high absolute risk at combined therapy with regards to anti-platelet. The utilization of aspirin drug, also significantly differ the health study at mortality rate (36) WHS including non-fatal heart diseases contributing to the presuming of stroke management the unknown analog to see the differences. (37) Therefore, the androgen role at combined estrogen level worsen the situation at demonstrating the comparable cases that compel the progesterone role in the chronic treatment inducing the module of traumatic injury in brain (PROTECT) to calculate (GCS) at severity likely at randomized placebo trials, seen in table: 4 undergoing the mediation of self assessed genetic owing XY and XX cells in the influences of sex steroids. (38, 39, 40) The amplified phase in the propagation of platelet-bound complexes generates the complexity with stable conditions to disrupt the thrombolysis in the existence of TPA plasminogen dissolving pathologic occlusion and eventual infarcts. Consequently, in the platelet functioning, the hormonal differences predominate the estrogen in females at ovulation period illustrating the postmenopausal and prepubertal cycles in both sexes. (41) Conversely, replacement therapy synthetically delineate the preventive measures and improvements (42) by exhibiting the replacement therapy to suppress the pathways of vascular dysfunction in restoring the influenced success rate (22) by repeatedly adding multiple procedures in the discovery of normal sinus rhythm that required a preferences of recommendation motion to clear fewer rate of causes in men's. (43)

Table: 4 Safety outcomes for major antithrombic comparison

According to the previous studies in the majority of guidelines result in 2014 concluded the equally similar progress at anti-coagulants follow-up NOAS, but the secondary observed analysis highly residue the risk of women's in a controversial era at a cohort broader explanations. (37) Lastly, the heterogeneity in larger studies adjusted only 8%thrombic events in the sizes and uncertain estimation. Regardless VASC use to proportional the warfarin trial relevantly in the recognition of MI at current issue of controlled sex analysis. (44, 45) Table .5

CONCLUSION

The existence of pathophysiology in acute MI prevention give similar results between males and females, but occasionally evident certain complications slightly higher in females in the personalized measures of a balanced approach in the beneficial treatment at cardiac risk factors. And also the interactive efficacies risk the anti-platelet drugs in to convincing the comparison of future guidelines in an adequate conducted sex differences specifying the examined receiving quantity for the further conceptual framework. Moreover, the limited outcomes in the association of antithrombic pharmacological effects assume one-third results (38) at symptomatic ranges of CHD eligibility. And the targets in females in the participation of study enrollment approve the affirmative action at the improved trials of endpoints in the major references representing less ascertainment.

Limitations

The common registries and competence of accurate data materials standardize the limits at the bias of obtaining murmur dysfunctions; the variable of lifespan, generalized treated dosing linking the differentiated management. In conclusion, clinical presentation and its leading outcome factor largely cohort the research in the individualized system taking non-pharmacological symptomatic results to reach preventive strategies into epidemic worldwide.

Conflicts of interest

The authors indicated no potential conflicts of interest.

References

1. January, C. T. *et al*. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fbrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. *Circulation* 130, e199–267 (2014).
2. Wolf, P. A., Abbott, R. D. & Kannel, W. B. Atrial fbrillation as an independent risk factor for stroke: the Framingham Study. *Stroke* 22, 983–988 (1991).
3. Benjamin, E. J. *et al*. Independent risk factors for atrial fbrillation in a population-based cohort. Te Framingham Heart Study. *JAMA* 271, 840–844 (1994).
4. Kannel, W. B., Abbott, R. D., Savage, D. D. & McNamara, P. M. Epidemiologic features of chronic atrial fbrillation: the Framingham study. *N Engl J Med* 306, 1018–1022 (1982)
5. Burr ML, Butland BK. Heart disease in British vegetarians. Am J Clin Nutr 1988;48 Suppl:830–2.
6. Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002;137:273–84
7. Kushi LH, Folsom AR, Prineas RJ, *et al*. Dietary antioxidant vitamins and eath from coronary heart disease in postmenopausal women. N Engl J Med 1996;334:1156–62.
8. Lapidus L, Andersson H, Bengtsson C, *et al*. Dietary habits in relation to incidence of cardiovascular disease and death in women: a 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Am J Clin Nutr 1986;44:444–8.
9. Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. *Lancet* 2011;378: 1297-305. doi:10.1016/ S0140-6736(11)60781-2. 21839503
10. Peters SAE, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women

compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. *Diabetologia* 2014;57: 1542-51. doi:10.1007/s00125-014-3260-6. 24859435

11. Clark, D. M., Plumb, V. J., Epstein, A. E. & Kay, G. N. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fbrillation. *J Am Coll Cardiol* 30, 1039–1045 (1997)
12. Luo, C. *et al*. Predictive value of coronary blood flow for future cardiovascular events in patients with atrial fbrillation. *Int J Cardiol* 177, 545–547 (2014)
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. [PMID: 3802833]
14. Marcucci R, Cioni G, Giusti B, *et al*. Gender and anti-thrombotic therapy: from biology to clinical implications. J Cardiovasc Transl Res 2014; 7: 72-81.
15. Patti G, De Caterina R, Abbate R, *et al*; Working Group on Thrombosis of the Italian Society of Cardiology. Platelet function and long-term antiplatelet therapy in women: is there a gender-specifcity? A 'state-of-the-art' paper. Eur Heart J 2014; 35: 2213-23b
16. Baigent C, Blackwell L, Collins R, *et al*; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60
17. Wiviott SD, Braunwald E, McCabe CH, *et al*; for the TRITON–TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-15
18. Gutiérrez-Chico JL, Mehilli J. Gender differences in cardiovascular therapy: focus on antithrombotic therapy and percutaneous coronary intervention.*Drugs* 2013;73:1921–1933.Google Scholar Crossref PubMed
19. Yu J, Mehran R, Grinfeld L, Xu K , Nikolsky E, Brodie BR , Witzenbichler B, Kornowski R, Dangas GD, Lansky AJ, Stone GW. Sex-based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: three year results from the HORIZONS-AMI trial. *Catheter Cardiovasc Interv* 2015 ;85:359 –368 Google Scholar Crossref PubMed
20. Poon S, Goodman SG, Yan RT, Bugiardini R, Bierman AS, Eagle KA , Johnston N, Huynh T, Grondin FR, Schenck-Gustafsson K, Yan AT. Bridging the gender gap: insights from a contemporary analysis of sex-related differences in the treatment and outcomes of patients with acute coronary syndromes. *Am Heart J* 2012;163:66–73. Google Scholar Crossref PubMed
21. Tavris D, Shoaibi A, Chen AY, Uchida T, Roe MT, Chen J. Gender differences in the treatment of non-ST-segment elevation myocardial infarction. *Clin Cardiol* 2010; 33:99–103. Google Scholar Crossref PubMed
22. Blomkalns AL, Chen AY, Hochman JS, Peterson ED, Trynosky K, Diercks DB, Brogan GX Jr, Boden WE, Roe MT, Ohman EM, Gibler WB, Newby LKE, CRUSADE Investigators. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. *J Am Coll Cardiol* 2005;45:832–837.Google Scholar Crossref PubMed
23. Wang TY, McCoy L, Henry TD, Effron MB, Messenger JC, Cohen DJ, Mark DB, Stone GW, Zettler M, Singh M, Fonarow GC, Peterson ED,TRANSLATE-ACS Study Investigators. Early post-discharge bleeding and antiplatelet therapy discontinuation among acute myocardial infarction patients treated with percutaneous coronary intervention. *J Am Coll Cardiol* 2014;63:1700–1702. Google Scholar Crossref PubMed
24. Sullivan RM, Zhang J, Zamba G, Lip GY, Olshansky B. Relation of gender-specifc risk of ischemic stroke in patients with atrial fbrillation to differences in warfarin anticoagulation control (from AFFIRM). Am J Cardiol 2012; 110: 1799-802
25. Fang MC, Singer DE, Chang Y, *et al*. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fbrillation: the AnTicoagulation and Risk factors In Atrial fbrillation (ATRIA) study. Circulation 2005; 112:1687–91.
26. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. Thromb Haemost 2009; 101: 938–42
27. Kelly AB, Maraganore JM, Bourdon P, Hanson SR, Harker LA. Antithrombotic effect of synthetic peptides targeting various functional domains of thrombin. Proc Natl Acad Sci U S A. 1992;89: 6040-6044.
28. Maraganore JM, Bourdon P, Adelman B, Cannon C, Theroux P. Heparin variability and resistance: comparisons with a direct thrombin inhibitor. Circulation. 1992;86(suppl I):I-386. Abstract.
29. 29. Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood. 1991;77:1006-1012.
30. 30 Klement P, Borm A, Hirsh J, Maraganore J, Wilson G, Weitz J. The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model. Thromb Haemost. 1992;68: 64-68.
31. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina following discontinuation of heparin. N Engl J Med. 1992;327:141-145.
32. Potpara TS ,Marinkovic JM , Polovina MM , *et al* .Gender-related differences in presentation, treatment and long-term outcome in patients with first-diagnosed atrial fibrillation and structurally normal heart: the Belgrade atrial fibrillation study. *Int J Cardiol* 2012*;*161*:*39–44. doi:10.1016/j.ijcard.2011.04.022 CrossRef PubMed Google Scholar
33. Lip GY, Laroche C, Boriani G , *et al* .Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atria Fibrillation*. Europace* 2015*;*17*:*24–31. doi:10.1093/europace/euu155 CrossRef PubMed Google Scholar
34. Calkins H, Kuck KH ,Cappato R , *et al* HRS/EHRA/ECAS expert consensus statement on

catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. *Heart Rhythm* 2012*;9:*63296.CrossRefPubMedWeb of ScienceGoogle Scholar

35. Forleo GB,Tondo C , De Luca L , *et al* .Gender-related differences in catheter ablation of atrial fibrillation. *Europace*2007*;9:*613 20.doi:10.1093/europace/eum144CrossRefPubMedWeb of ScienceGoogle Scholar
36. Vinereanu D, Stevens SR, Alexander JH, *et al* .Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. *Eur HeartJ* 2015*;*36*:*326875.doi:10.1093/eurheartj/ehv447CrossRefPubMedGoogle Scholar
37. Humphries KH, Kerr CR, Connolly SJ, *et al* .New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. *Circulation* 2001*;*103*:*236570.doi:10.1161/01.CIR.103.19.2365Abstract/FREE Full TextGoogle Scholar
38. Lisabeth LD, Roychoudhury C, Brown DL, Levine SR. Do gender and race impact the use of antithrombotic therapy in patients with stroke/TIA? Neurology. 2004;62(12):2313–2315. [PubMed] •• Study that highlights the significantly higher use of antithrombotic therapy in men as compared to women for secondary stroke prevention.
39. Arnold A, Burgoyne P. Are XX and XY brain cells intrinsically different? Trends Endocrinol. Metab. 2004;15(1):6–11. [PubMed]
40. Heyer A, Hasselblatt M, von Ahsen N, Hafner H, Siren A-L, Ehrenreich H. *In vitro* gender differences in neuronal survival on hypoxia and in 17[β]-estradiol-mediated neuroprotection. J. Cereb. Blood Flow Metab. 2005;25(4):427–433. [PubMed]
41. Goroll AH, Mulley AG., Jr . Gynecologic Problems. In: Goroll AH, Mulley AG Jr, editors. Primary Care Medicine (4th Edition) PA, USA: Lippincott, Williams & Wilkins; 1995. pp. 667–738.
42. Rossouw JE, Anderson GL, Prentice RL, *et al*. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA. 2002;288(3):321–333.[PubMed]
43. Winkle RA , Mead RH, Engel G , *et al* . Long-term results of atrial fibrillation ablation: the importance of all initial ablation failures undergoing a repeat ablation. *Am Heart J* 2011*;*162*:*193–200.doi:10.1016/j.ahj.2011.04.013CrossRefPubMedWeb of ScienceGoogle Scholar
44. Soliman EZ, Lopez F, O'Neal WT , *et al.* Atrial Fibrillation and risk of ST-segment-elevation versus non-ST-segment-slevation myocardial infarction: the Atherosclerosis risk in communities (ARIC) study. *Circulation* 2015*;*131*:*184350.doi:10.1161/CIRCULATIONAHA.114.014145Abstract/FREE Full TextGoogle Scholar
45. Soliman EZ, Safford MM, Muntner P , *et al* . Atrial fibrillation and the risk of myocardial infarction. *JAMA Intern Med* 2014*;*174*:*107–14.doi:10.1001/jamainternmed.2013.11912CrossRefPubMedGoogle Scholar

How to cite this article:

Hassah Iftikhar, Hassam Ali and Ya Li (2019) ' Clinical Outcome in Atria Fibrillation at Gender Differences: Meta- Analysis', *International Journal of Current Advanced Research,* 08(04), pp. 18228-18234.
DOI: http://dx.doi.org/10.24327/ijcar.2019.18234.3479

****